Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study

Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study

ABSTRACTWe aimed to evaluate sarcopenia and sarcopenic obesity (SO) in patients with type 2 diabetes mellitus (T2DM), possible relationships with serum irisin and myostatin levels, and the effect of glycemic control on SO.Ninety T2DM patients were included in this a cross-sectional study. Sarcopenia...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medicine (Baltimore) 2021-07, Vol.100 (26), p.e26529-e26529
Hauptverfasser: Oguz, Ayten, Sahin, Murat, Tuzun, Dilek, Kurutas, Ergul B., Ulgen, Cansu, Bozkus, Ozlem, Gul, Kamile
Format: Artikel
Sprache:eng
Schlagworte:
Observational Study
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e26529
container_issue 26
container_start_page e26529
container_title Medicine (Baltimore)
container_volume 100
creator Oguz, Ayten
Sahin, Murat
Tuzun, Dilek
Kurutas, Ergul B.
Ulgen, Cansu
Bozkus, Ozlem
Gul, Kamile
description ABSTRACTWe aimed to evaluate sarcopenia and sarcopenic obesity (SO) in patients with type 2 diabetes mellitus (T2DM), possible relationships with serum irisin and myostatin levels, and the effect of glycemic control on SO.Ninety T2DM patients were included in this a cross-sectional study. Sarcopenia was determined by evaluating muscle mass (bioelectrical impedance analysis), muscle strength (HGS), and gait speed (GS). Patients with muscle mass loss with functionally reduced muscle strength and/or performance were considered sarcopenic. In addition, participants were divided into 3 groups according to the FM (fat mass)/FFM (fat-free mass) ratio [group 1:5th-50th percentiles; group 2:50th-95th percentiles and group 3: ≥95 percentiles (sarcopenic obese)]. Irisin, myostatin levels and metabolic parameters were measured in all patients.The prevalence of sarcopenia and SO was 25.6% and 35.6%, respectively. Irisin levels were lower in sarcopenic patients, while glycosylated hemoglobin (A1c), body mass index (BMI), FM, and FM index were higher (P 
doi_str_mv 10.1097/MD.0000000000026529
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8257893</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2546975722</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3327-cf77baa7b0bac4ae4f8c219f52a7e7955d2fa08f71fc61f45b1b279e1414fce73</originalsourceid><addsrcrecordid>eNpdUU1v1TAQtBCIPgq_gIuPXFL8mY05IFUtH5Va9VLOxnHWPENeHGyn1fv3hL4K1O5lpdmZWY2GkLecnXBm4P3V-Qn7P6LVwjwjG65l22jTqudks6K6AQPqiLwq5SdjXIJQL8mRVNww3nUb8v0ixxInGgt1dM44RF9TpinQ4rJPM07R09RjiXVPV17dz0gFHaLrsWKhOxzHWJfygZ5Sn1MpTUFfY5rcSEtdhv1r8iK4seCbh31Mvn3-dHP2tbm8_nJxdnrZeCkFND4A9M5Bz3rnlUMVOi-4CVo4QDBaDyI41gXgwbc8KN3zXoBBrrgKHkEek48H33npdzh4nGp2o51z3Lm8t8lF-_gyxa39kW5tJzR0Rq4G7x4Mcvq9YKl2F4tf47kJ01Ks0Ko1oEGIlSoP1PvEGcO_N5zZv93Yq3P7tJtVpQ6quzRWzOXXuNxhtlt0Y93e0zUY0QgmOAMmWLMiCuQf7HCRzA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2546975722</pqid></control><display><type>article</type><title>Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study</title><source>Wolters Kluwer Open Health</source><source>DOAJ Directory of Open Access Journals</source><source>IngentaConnect Free/Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Oguz, Ayten ; Sahin, Murat ; Tuzun, Dilek ; Kurutas, Ergul B. ; Ulgen, Cansu ; Bozkus, Ozlem ; Gul, Kamile</creator><creatorcontrib>Oguz, Ayten ; Sahin, Murat ; Tuzun, Dilek ; Kurutas, Ergul B. ; Ulgen, Cansu ; Bozkus, Ozlem ; Gul, Kamile</creatorcontrib><description>ABSTRACTWe aimed to evaluate sarcopenia and sarcopenic obesity (SO) in patients with type 2 diabetes mellitus (T2DM), possible relationships with serum irisin and myostatin levels, and the effect of glycemic control on SO.Ninety T2DM patients were included in this a cross-sectional study. Sarcopenia was determined by evaluating muscle mass (bioelectrical impedance analysis), muscle strength (HGS), and gait speed (GS). Patients with muscle mass loss with functionally reduced muscle strength and/or performance were considered sarcopenic. In addition, participants were divided into 3 groups according to the FM (fat mass)/FFM (fat-free mass) ratio [group 1:5th-50th percentiles; group 2:50th-95th percentiles and group 3: ≥95 percentiles (sarcopenic obese)]. Irisin, myostatin levels and metabolic parameters were measured in all patients.The prevalence of sarcopenia and SO was 25.6% and 35.6%, respectively. Irisin levels were lower in sarcopenic patients, while glycosylated hemoglobin (A1c), body mass index (BMI), FM, and FM index were higher (P &lt; .05). From group 1 to group 3, BMI, FM, FM index, GS, myostatin, and A1c increased, and muscle mass percentage, HGS, and irisin decreased (P &lt; .05). A positive correlation was found between FM/FFM and myostatin and a negative correlation between FM/FFM and irisin (r = 0.303, P = .004 vs. r = -0.491, P &lt; .001). Irisin remained an important predictor of SO, even after adjusting for confounding variables (OR:1.105; 95% CI:0.965-1.338, P = .002). The optimal cut-off value for irisin to predict SO was 9.49 ng/mL (specificity = 78.1%, sensitivity = 75.8%). In addition, A1c was an independent risk factor for SO development (OR:1.358, P = .055).This study showed that low irisin levels (&lt;9.49ng/mL) and poor glycemic control in T2DM patients were an independent risk factor, especially for SO.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000026529</identifier><identifier>PMID: 34190188</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams &amp; Wilkins</publisher><subject>Observational Study</subject><ispartof>Medicine (Baltimore), 2021-07, Vol.100 (26), p.e26529-e26529</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3327-cf77baa7b0bac4ae4f8c219f52a7e7955d2fa08f71fc61f45b1b279e1414fce73</cites><orcidid>0000-0002-9518-8610</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257893/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8257893/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids></links><search><creatorcontrib>Oguz, Ayten</creatorcontrib><creatorcontrib>Sahin, Murat</creatorcontrib><creatorcontrib>Tuzun, Dilek</creatorcontrib><creatorcontrib>Kurutas, Ergul B.</creatorcontrib><creatorcontrib>Ulgen, Cansu</creatorcontrib><creatorcontrib>Bozkus, Ozlem</creatorcontrib><creatorcontrib>Gul, Kamile</creatorcontrib><title>Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study</title><title>Medicine (Baltimore)</title><description>ABSTRACTWe aimed to evaluate sarcopenia and sarcopenic obesity (SO) in patients with type 2 diabetes mellitus (T2DM), possible relationships with serum irisin and myostatin levels, and the effect of glycemic control on SO.Ninety T2DM patients were included in this a cross-sectional study. Sarcopenia was determined by evaluating muscle mass (bioelectrical impedance analysis), muscle strength (HGS), and gait speed (GS). Patients with muscle mass loss with functionally reduced muscle strength and/or performance were considered sarcopenic. In addition, participants were divided into 3 groups according to the FM (fat mass)/FFM (fat-free mass) ratio [group 1:5th-50th percentiles; group 2:50th-95th percentiles and group 3: ≥95 percentiles (sarcopenic obese)]. Irisin, myostatin levels and metabolic parameters were measured in all patients.The prevalence of sarcopenia and SO was 25.6% and 35.6%, respectively. Irisin levels were lower in sarcopenic patients, while glycosylated hemoglobin (A1c), body mass index (BMI), FM, and FM index were higher (P &lt; .05). From group 1 to group 3, BMI, FM, FM index, GS, myostatin, and A1c increased, and muscle mass percentage, HGS, and irisin decreased (P &lt; .05). A positive correlation was found between FM/FFM and myostatin and a negative correlation between FM/FFM and irisin (r = 0.303, P = .004 vs. r = -0.491, P &lt; .001). Irisin remained an important predictor of SO, even after adjusting for confounding variables (OR:1.105; 95% CI:0.965-1.338, P = .002). The optimal cut-off value for irisin to predict SO was 9.49 ng/mL (specificity = 78.1%, sensitivity = 75.8%). In addition, A1c was an independent risk factor for SO development (OR:1.358, P = .055).This study showed that low irisin levels (&lt;9.49ng/mL) and poor glycemic control in T2DM patients were an independent risk factor, especially for SO.</description><subject>Observational Study</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdUU1v1TAQtBCIPgq_gIuPXFL8mY05IFUtH5Va9VLOxnHWPENeHGyn1fv3hL4K1O5lpdmZWY2GkLecnXBm4P3V-Qn7P6LVwjwjG65l22jTqudks6K6AQPqiLwq5SdjXIJQL8mRVNww3nUb8v0ixxInGgt1dM44RF9TpinQ4rJPM07R09RjiXVPV17dz0gFHaLrsWKhOxzHWJfygZ5Sn1MpTUFfY5rcSEtdhv1r8iK4seCbh31Mvn3-dHP2tbm8_nJxdnrZeCkFND4A9M5Bz3rnlUMVOi-4CVo4QDBaDyI41gXgwbc8KN3zXoBBrrgKHkEek48H33npdzh4nGp2o51z3Lm8t8lF-_gyxa39kW5tJzR0Rq4G7x4Mcvq9YKl2F4tf47kJ01Ks0Ko1oEGIlSoP1PvEGcO_N5zZv93Yq3P7tJtVpQ6quzRWzOXXuNxhtlt0Y93e0zUY0QgmOAMmWLMiCuQf7HCRzA</recordid><startdate>20210702</startdate><enddate>20210702</enddate><creator>Oguz, Ayten</creator><creator>Sahin, Murat</creator><creator>Tuzun, Dilek</creator><creator>Kurutas, Ergul B.</creator><creator>Ulgen, Cansu</creator><creator>Bozkus, Ozlem</creator><creator>Gul, Kamile</creator><general>Lippincott Williams &amp; Wilkins</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9518-8610</orcidid></search><sort><creationdate>20210702</creationdate><title>Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study</title><author>Oguz, Ayten ; Sahin, Murat ; Tuzun, Dilek ; Kurutas, Ergul B. ; Ulgen, Cansu ; Bozkus, Ozlem ; Gul, Kamile</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3327-cf77baa7b0bac4ae4f8c219f52a7e7955d2fa08f71fc61f45b1b279e1414fce73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Observational Study</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oguz, Ayten</creatorcontrib><creatorcontrib>Sahin, Murat</creatorcontrib><creatorcontrib>Tuzun, Dilek</creatorcontrib><creatorcontrib>Kurutas, Ergul B.</creatorcontrib><creatorcontrib>Ulgen, Cansu</creatorcontrib><creatorcontrib>Bozkus, Ozlem</creatorcontrib><creatorcontrib>Gul, Kamile</creatorcontrib><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oguz, Ayten</au><au>Sahin, Murat</au><au>Tuzun, Dilek</au><au>Kurutas, Ergul B.</au><au>Ulgen, Cansu</au><au>Bozkus, Ozlem</au><au>Gul, Kamile</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study</atitle><jtitle>Medicine (Baltimore)</jtitle><date>2021-07-02</date><risdate>2021</risdate><volume>100</volume><issue>26</issue><spage>e26529</spage><epage>e26529</epage><pages>e26529-e26529</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>ABSTRACTWe aimed to evaluate sarcopenia and sarcopenic obesity (SO) in patients with type 2 diabetes mellitus (T2DM), possible relationships with serum irisin and myostatin levels, and the effect of glycemic control on SO.Ninety T2DM patients were included in this a cross-sectional study. Sarcopenia was determined by evaluating muscle mass (bioelectrical impedance analysis), muscle strength (HGS), and gait speed (GS). Patients with muscle mass loss with functionally reduced muscle strength and/or performance were considered sarcopenic. In addition, participants were divided into 3 groups according to the FM (fat mass)/FFM (fat-free mass) ratio [group 1:5th-50th percentiles; group 2:50th-95th percentiles and group 3: ≥95 percentiles (sarcopenic obese)]. Irisin, myostatin levels and metabolic parameters were measured in all patients.The prevalence of sarcopenia and SO was 25.6% and 35.6%, respectively. Irisin levels were lower in sarcopenic patients, while glycosylated hemoglobin (A1c), body mass index (BMI), FM, and FM index were higher (P &lt; .05). From group 1 to group 3, BMI, FM, FM index, GS, myostatin, and A1c increased, and muscle mass percentage, HGS, and irisin decreased (P &lt; .05). A positive correlation was found between FM/FFM and myostatin and a negative correlation between FM/FFM and irisin (r = 0.303, P = .004 vs. r = -0.491, P &lt; .001). Irisin remained an important predictor of SO, even after adjusting for confounding variables (OR:1.105; 95% CI:0.965-1.338, P = .002). The optimal cut-off value for irisin to predict SO was 9.49 ng/mL (specificity = 78.1%, sensitivity = 75.8%). In addition, A1c was an independent risk factor for SO development (OR:1.358, P = .055).This study showed that low irisin levels (&lt;9.49ng/mL) and poor glycemic control in T2DM patients were an independent risk factor, especially for SO.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>34190188</pmid><doi>10.1097/MD.0000000000026529</doi><orcidid>https://orcid.org/0000-0002-9518-8610</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2021-07, Vol.100 (26), p.e26529-e26529
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8257893
source Wolters Kluwer Open Health; DOAJ Directory of Open Access Journals; IngentaConnect Free/Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Observational Study
title Irisin is a predictor of sarcopenic obesity in type 2 diabetes mellitus: A cross-sectional study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T13%3A10%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Irisin%20is%20a%20predictor%20of%20sarcopenic%20obesity%20in%20type%202%20diabetes%20mellitus:%20A%20cross-sectional%20study&rft.jtitle=Medicine%20(Baltimore)&rft.au=Oguz,%20Ayten&rft.date=2021-07-02&rft.volume=100&rft.issue=26&rft.spage=e26529&rft.epage=e26529&rft.pages=e26529-e26529&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000026529&rft_dat=%3Cproquest_pubme%3E2546975722%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2546975722&rft_id=info:pmid/34190188&rfr_iscdi=true